Chronic Hepatitis News

Researchers identified a common polymorphism and a rare variant combination in hepatitis C genotype 3 that are responsible for a reduced response to Sovaldi, according to a study published in Gastroenterology.

Reports of hepatitis A infections increased by nearly 300% in the U.S. between 2016 and 2018 compared with 2013 to 2015, primarily due to outbreaks associated with contaminated food items, men who have sex with men, and people who report drug use or homelessness, according to the CDC.

In these exclusive videos from the International Liver Congress 2019, hepatology experts and liver disease advocates provide updates on the global efforts for hepatitis elimination, including both hepatitis B and hepatitis C.

Dicerna dosed the first patient in a phase 1 clinical trial for DCR-HBVS, an investigational GalXCTM-based therapy for the treatment of chronic hepatitis B, according to a press release.

Results from the EGALITE study showed that 12 weeks of elbasvir/grazoprevir was a highly effective regimen for treatment-naive Asian patients with hepatitis C virus genotype 1b infection and mild liver fibrosis. Those who were given 8 weeks of therapy had “substantially lower” SVR12 rates, researchers said, suggesting that only certain patients — like those with low viral loads and patients without significant resistance to NS5A inhibitor-containing regimens — can benefit from an abbreviated regimen.

Durect Corporation announced preliminary data from an ongoing phase 2a trial of DUR-928 for alcohol-related hepatitis, according to a press release.

Promethera Biosciences dosed the first patient in a phase 2a clinical study of HepaStem for patients with late stage nonalcoholic steatohepatitis, according to a press release.

VIENNA — In this exclusive video from the International Liver Congress 2019, Philippa Easterbrook, MD, senior scientist of the Global Hepatitis Program within the HIV Department at the WHO headquarters in Geneva, Switzerland, discusses a symposium focused on sharing “good practices and lessons learned” in the global viral hepatitis response.

Early alcohol rehabilitation reduced 30-day readmission, alcohol relapse and mortality among patients hospitalized for alcohol-related hepatitis, according to data published in Clinical Gastroenterology and Hepatology.

The FDA approved Mavyret to treat all six genotypes of hepatitis C in pediatric patients aged 12 years to 17 years, according to a press release from the organization.